Bourgeon Capital Management LLC Has $939,000 Position in Johnson & Johnson (NYSE:JNJ)

Bourgeon Capital Management LLC raised its position in Johnson & Johnson (NYSE:JNJGet Rating) by 43.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,750 shares of the company’s stock after acquiring an additional 1,750 shares during the quarter. Bourgeon Capital Management LLC’s holdings in Johnson & Johnson were worth $939,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in JNJ. Taylor & Morgan Wealth Management LLC raised its position in shares of Johnson & Johnson by 1.6% in the second quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock valued at $635,000 after purchasing an additional 57 shares during the period. Red Wave Investments LLC raised its position in shares of Johnson & Johnson by 2.0% in the second quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock valued at $530,000 after purchasing an additional 59 shares during the period. Argus Investors Counsel Inc. increased its position in Johnson & Johnson by 0.6% during the second quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock worth $1,941,000 after acquiring an additional 61 shares during the period. Alta Capital Management LLC increased its position in Johnson & Johnson by 0.4% during the second quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock worth $2,808,000 after acquiring an additional 61 shares during the period. Finally, Paces Ferry Wealth Advisors LLC increased its position in Johnson & Johnson by 0.7% during the third quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock worth $1,425,000 after acquiring an additional 62 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on JNJ. Citigroup raised their price target on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Sanford C. Bernstein decreased their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Credit Suisse Group began coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price on the stock. Raymond James decreased their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19th. Finally, StockNews.com assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Seven research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $182.42.

Johnson & Johnson Stock Down 0.3 %

NYSE:JNJ opened at $173.43 on Monday. The firm’s 50 day simple moving average is $176.32 and its 200 day simple moving average is $171.47. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a market cap of $453.43 billion, a PE ratio of 24.15, a P/E/G ratio of 3.28 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business had revenue of $23.79 billion for the quarter, compared to the consensus estimate of $23.44 billion. During the same period last year, the company earned $2.60 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.61%. Johnson & Johnson’s payout ratio is 62.95%.

Insiders Place Their Bets

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Peter Fasolo sold 22,864 shares of the firm’s stock in a transaction that occurred on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the transaction, the vice president now owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The disclosure for this sale can be found here. In the last 90 days, insiders sold 300,750 shares of company stock worth $52,311,677. 0.35% of the stock is currently owned by insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.